At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
RAD001drug
Likely dose
RAD001 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating RAD001 for Metastatic Renal Cell Carcinoma. Completed, enrolled 134 participants across 17 sites in 6 countries.
Detailed Summary
This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior cytokines, 2) prior sunitinib, or 3) prior anti-VEGF therapy other than sunitinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesArgentina, Brazil, Bulgaria, China, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedDec 2011
Primary CompletionMay 2015
TodayJul 2026
First PostedDec 14, 2011
Enrollment StartNov 1, 2011
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 14.5 years ago
Interventions
RAD001drug
Study drug was supplied as 5 mg tablets in blister packs.